Furthermore, the pharmacokinetic profiles of the compound Id showed longer serum levels than that of ceftriaxone in rats. 507 In general, cephalosporin antibiotics of the so-called third generation possess very potent activity against Enterobacteriaceae, but weak or moderate activity against Staphylococcus aureus. Furthermore the activity of such a drug against methicillin-resistant S. aureus (MRSA)is very low. As a result of the spread of third generation cephalosporins, infectious disease due to S. aureus has progressively increased and become a serious problem, especially concerning MRSAin chemotherapy.2) Somecephalosporins with enhanced activity against S. aureus have been recently developed or introduced into therapy. 3) However, a cephalosporin possessing sufficient activity against MRSA has not been reported so far. The goal of our research effort was the synthesis of an injectable cephalosporin having excellent activity against S. aureus including MRSA,as well as Gram-negative bacteria.
A recent report1} from our laboratories has described the structure-activity relationships of 7-[2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetyl]cephalosporins with sterically small substituents relating to cefdinir (FK482), a new orally active cephalosporin. Most of the hydroxyimino compounds exhibited highly potent activity against methicillin-sensitive S. aureus (MSSA). However the activity of these compounds against MRSA was not so high as that of cefdinir.4)
3-Thiadiazolylthiomethyl cephalosporins such as cefazolin (CEZ), ceftezol (CTZ) and cefuzonam (CZON) show generally good anti-S. aureus activity.
Consequently, we synthesized various 3-thiadiazolylthiomethyl derivatives of the hydroxyimino cephalosporin and studied the structure-activity relationships. In our study we have found that 3-(l ,2,4-thiadiazol-5-yl)thiomethyl cephalosporin derivative (Id: FK312) shows the highest activity against MRSAas well as MSSA.Second, we directed our efforts towards the synthesis of 7j?-amino-3-(l ,2,4-thiadiazol-5-yl)thiomethyl cephalosporin derivatives with various alkoxyimino groups which seemed to be favorable for enhancement of activity against Gram-positive Paper XVIII: See ref 1. bacteria. Thus in this paper we report the preparation of 3-thiadiazolylthiomethyl cephalosporins (1 and 7), structure-activity relationships and further evaluation of FK312.
Biological Results and Discussion MICvalues of cephalosporin derivatives la~le against several Gram-positive and Gram-negative bacteria are shown in Table 1 compared with CZONand flomoxef (FMOX).lc and Id showed better activity against S. aureus 2538 (MRSA) than other derivatives, and Id had excellent activity (3.13 /xg/ml) against S. aureus 3004 (MRSA). Against Gram-negative bacteria, all of the compounds prepared here showed highly potent activities. This showed that (l,2,4-thiadiazol-5-yl)thiomethyl moiety might be the most suitable substituent at the 3-position for our purposes. Therefore, we tried to optimize the 7-acyl side chain of 3-(l,2,4-thiadiazol-5-yl)thiomethyl cephalosporin.
The antibacterial activity of 3-(l,2,4-thiadiazol-5-yl)thiomethyl cephalosporin derivatives (7 and Id) possessing various oxime moieties in the 7-acyl side chain are shown in Table 2 . Hydroxyimino compound Id exhibited better Grampositive and also Gram-negative antibacterial activity than alkoxyimino compounds 7a~7d, although cyclopentenyloxyimino compound (7c) showed excellent activity against Gram-positive bacteria. Consequently, Id (FK312) was selected as a candidate for further evaluation.
Antibacterial activity of Id against resistant S. aureus are shown in Table 3 compared with CZON and FMOX.Strains of S. aureus resistant to methicillin were highly susceptible to Id. All strains of S. aureus resistant to CZONand FMOX were also highly susceptible to Id. In the next step, the protective effects on mice infection and the pharmacokinetic profiles in rats after intravenous injection of compound Id were evaluated. Protective activities of Id against two kinds of S. aureus infection in mice are indicated in Table 4 , compared with CZONand FMOX. Against S. aureus 47 the effects of Id were superior to that of FMOX and CZON,and against S. aureus 2499 similar to that of FMOX. The pharmacokinetic parameters and the plasma levels of Id in rats after intravenous injection are indicated in Table 5 and Fig. 1 and are compared with CTRXand CZON.The half-lives of Id was 54 minutes and the area under the curve (AUC) was 181 /ig-hour/ml. These results indicate that compound Id exhibited a longer half-life than CTRX.Thus, serum protein binding of Id was examined to evaluate its long-acting effect. The serum protein binding of Id was considerably high as shown in Table 6 . The binding value of Id was 97.5% for rat which was higher than that of CTRX.The high value seems to reflect the long acting property of Id.
Chemistry 7j5-[(Z)-2-(2-Amino-4-thiazolyl)-2-hydroxyiminoacetamido]cephalosporins
(lb~le) were prepared as outlined in Scheme 1. As the Method A, 7-aminocephalosporin derivatives (2c and 2d) was treated with 4-chloroacetoacetyl chloride in the presence of l ,3-bis(trimethylsilyl)urea (BSU) to give the acylated compound 3. Nitrosation of 3 with aqueous sodium nitrite gave the hydroxime compound4. 4 was reacted with thiourea in 7V,iV-dimethylacetamide (DMAc) to give the thiazole derivatives (lc and Id). As the Method B, the acid (5) was activated with the Vilsmeier reagent, prepared from DMFand phosphoryl chloride (POC13). The protecting trityl and tetrahydropyranyl groups of 6b and 6e were removedby treatment with coned hydrochloric acid in methanol to give lb and le. The spectral data of compoundslb~le are shownin proceeded at room temperature in MeOHcontaining coned hydrochloric acid. The trityl group of 9d was cleaved at room temperature by treatment with formic acid. The spectral data of these final compounds (7a~7d) are shown in Table 8 .
Experimental
NMR spectra were recorded at 60MHzon a JNM-PMX 60NMR spectrometer and at 100MHzon a Jeol-MHIOONMR spectrometer using TMSas an internal standard. IR spectra were taken on a Hitachi 260-10 spectrophotometer or Shimadzu IR-420 spectrophotometer.
Assay Procedure for Pharmacokinetics
Drug concentrations were measured by the disk-plate diffusion technique using Bacillus subtilis ATCC 6633 as the test organism and sodium citrate agar (sodium citrate 1.0%, agar 1.0%, Polypeptone 0.5%, and beef extract 0.3%) as the test medium. The plates were incubated at 37°C for 18 to 20 hours, and zones of inhibition were measured and compared with similarly prepared standards.
Binding to Serum Protein 515 A 0.5 ml volume of an antibiotic soluotion (300^g/ml) in 0.067 m phosphate buffer (pH 7.0) was added to 4.5 ml of fresh serum and incubated at 37°C for 1 hour. This mixture was placed in a Visking tube (size 8/32) and centrifuged at 1,000 x g for 30 to 40 minutes to obtain the ultrafiltrate.
The drug concentration in the filtrate was bioassayed using standard solutions prepared with 0.067 m phosphate buffer (pH 7.0). The degree of binding of the antibiotics was calculated in a conventional manner.
Antibiotic Susceptibility MICs were determined by the agar dilution method using Heart-Infusion agar (Difco). MICs were read after incubation at 37°C for 18 hours. Compoundla was prepared according to the method of the literature.5)
General Procedure for Acylation of 2c and 2d To a solution of2c or 2d (30 mmol) and BSU (90 mmol) in THF (200 ml) was added 4-chloroacetoacetyl chloride (36mmol) at -20°C, and the mixture was stirred at the same temperature for 1 hour. To the reaction mixture were added EtOAc(200ml) and H2O(200ml) and the mixture was adjusted to pH 6.5 with 5% NaHCO3soln.
The separated aq layer was adjusted to pH 3.0 with 10%HC1, and extracted with EtOAc. The extract was washed with brine, dried (MgSO4), and concentrated under reduced pressure. The residue was triturated with diisopropyl ether (IPE) to give 3c (79%), 3d (81%).
General Preparation of 4c and 4d
To a solution of3c or 3d (13.5mmol) in AcOH(50ml) was added a soln ofNaNO2 (17.6mmol) in H2O(7.7ml) at 5~10°C under stirring. The mixture was stirred at the same temperature for 1.5hours. The reaction mixture was poured into a mixture of EtOAc (200ml) and H2O(200ml) . The separated organic layer was washed with H2Oand brine, and dried (MgSO4). The organic solvent was evaporated in vacuo, and to the residue was added IPE. The resultant precipitate was collected by filtration to give 4c (81%), 4d (93%).
General Procedure for Cyclization of 4c and 4d with Thiourea To a solution of 4c or 4d (9.42mmol) in DMAc(35ml) was added thiourea (9.42mmol) at room temperature. The mixture was stirred at the sametemperature for 3 hours. The reaction mixture was poured into H2O (200ml) , and adjusted to pH 3.0 with 10% HC1 to form a precipitate.
The collected precipitate was dissolved in 5% NaHCO3 soln and was washed with EtOAc. The separated aq soln was acidified to pH 3.0 with 10% HC1under ice-cooling. The resultant precipitate was collected by filtration and dried to afford 1c (80%), Id (83%).
General Procedure for Acylation of 2b, 2d and 2e To a mixture ofDMF (32mmol) and THF (150ml) was added dropwise POC13 (32 mmol) at -10~0°C under stirring, and the mixture was stirred at this temperature for a further 30minutes to prepare the Vilsmeier reagent. To the above mixture was added the acid (56) or 8a~8c) (29 mmol) under ice-cooling, and the mixture was stirred at the same temperature for 1 hour to produce an activated acid soln of 5 or 8a~8c. To a mixture of 8d (29mmol) in DMF(250ml) was added diisopropylethylamine (58 mmol) and the methanesulfonyl chloride (58 mmol), and the mixture was stirred at -30°C for 30 minutes to prepare an activated acid soln of 8d.
To a soln of 2 (29mmol) and N-trimethylsilylacetamide (MSA) (200mmol) in THF (200ml) was added the above activated acid soln at -20°C, and the mixture was stirred at the same temperature for 30-60 minutes. To the reaction mixture were added EtOAc (200ml) and H2O(200ml) . The separated organic layer was washed with brine, and dried (MgSO4). The solvent was evaporated in vacuo, and the residue was triturated with IPE to afford 6b (82%), 6e (85%), 9a (90%), 9b (87%), 9c (59%) and 9d (51%).
General Procedure for Deprotection of 6b and 6e MAY 1991 To a mixture of6b or 6e (23.8mmol) in MeOH(200ml) was added coned HC1 (20ml) at room temperature, and the mixture was stirred at 30~35°C for 2 hours. The reaction mixture was neutralized with 5%NaHCO3soln under ice-cooling and concentrated under reduced pressure. The residue was dissolved in mixture of EtOAcand H2O. The separated aq layer was adjusted to pH 3.0 with 10%HC1under stirring. The resultant precipitate was collected by filtration to give lb (15%), le (10%).
General Procedure for Deformylation of 9a~9c To a mixture of a AMbrmyl derivative (6.9mmol), MeOH(70ml) and THF (20ml) was added coned HC1 (2.5 ml) at room temperature, and the mixture was stirred at the same temperature for 1 hour. The resultant mixture was neutralized with 5%NaHCO3 soln and concentrated under reduced pressure. The residue was dissolved in a mixture of EtOAcand H2O. The mixture was acidified to pH 3.0 with 10% HC1. The separated organic layer was washed with brine, and dried (MgSO4). The solvent was evaporated in vacuo and the residue was triturated with IPE to give 7a (61%), 7b (67%), 7c (56%).
Procedure for Detritylation of 9d
To a mixture of9d (8.6mmol) in HCOOH(65 ml) was added H2O (20ml) under ice-cooling, and the mixture was stirred at the same temperature for 3 hours. The resultant mixture was poured into H2O (100ml), adjusted to pH 7.0 with 5% NaHCO3soln. After being washed with EtOAc, the aq soln was adjusted to pH 3.5 with 10% HC1, and extracted with EtOAc. The extract was washed with brine, dried (MgSO4). The solvent was evaporated in vacuo and the residue was triturated with IPE to give 7d (85%).
